Dr. Anish Maroo

Dr. Anish Maroo
Oncologist, Delhi

MBBS, MD (Gen Med), DM (Medical Oncology)

  • 1 Hospital
  • 17 Years Experience


  • Oncology

  • Hematology

  • Medical Oncology



MBBS, 1991, SMS Medical College, Jaipur, India

DM (Medical Oncology), 1999, Kidwai Memorial Institute of Oncology, Bangalore, India

Practice Information

Action Cancer Hospital, Delhi

Action Cancer Hospital, Delhi

A - 4, Paschim Vihar, Delhi, Delhi - 110063

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Anish Maroo and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Principal Investigator: A phase 1/2 study of the vascular disrupting agent IP XXX in combination with Docetaxel in patients with Advanced NSCLC
  • Principal Investigator: A multi-centre multinational phase III randomised study to evaluate the safety and efficacy pt treating colorectal cancer patients with recurrent liver metastases using Novel System plus chemotherapy as compared to chemotherapy alone
  • Principal Investigator: A phase III study of XXX plus YYY versus YYY alone in patients with advanced breast cancer previously treated with resistant to an anthracycline and who are taxane resistant
  • Principal Investigator: A randomised double-blind placebo controlled study to evaluate the long term safety & efficacy of XXX administration at 500mcg once every 3 weeks in anaemic subjects with advanced stage non small cell cancer receiving multi-cycle chemotherapy
  • Principal Investigator: A randomised double-blind placebo controlled Phase III study to assess the safety and efficacy of weekly XXX in combination with carboplatin and taxane in subjects with platinum sensitive ovarian cancer in first relapse
  • Principal Investigator: A Phase III multicentre open label study to evaluate the efficacy and the safety of drug XXX in chronic ITP
  • Principal Investigator: An international, randomised double-blinded Phase III efficacy study of XXX versus Placebo in subjects with unresectable locally advanced or metastatic medullary thyroid cancer
  • A Phase 3 randomised multi-centre open label study to compare XXX to YYY in subject with advanced renal cell carcinoma
  • A Phase 3 randomised open label two arm study of XXX Plus YYY versus ZZZ Plus YYY as first line treatment for Erb2 positive locally recurrent or mets breast cancer
  • A randomised multi-centre open label Phase 3 study to compare the efficacy & safety of XXX and YYY in subject with previously treated, wild type Kras, metastatic colorectal cancer
  • An international, multi-centre, randomised double-blinded study of XXX or placebo in combination with YYY in patients with multiple myeloma
  • A Phase 3 randomised double-blind placebo-controlled study for oral XXX in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens
  • Bioequivalence of XXX with Herceptin: Comparative PK, efficacy, safety and Immunogenicity evaluation of XXX versus Herceptin, both in combination with Docetaxel in Patients with Her2+ metastatic breast cancer: a double-blind, randomised, active control, parallel assignment, comparative Phase III, clinical trial with a post-trial open label extension phase
  • Global study to assess the addition of Bevacizuman to Carboplatin and Paclitaxel as first-line treatment of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma
  • A randomised Phase III study of imatinib dose optimisation compared with nilotinib in patients with chronic myelogenous leukaemia and suboptimal response to standard-dose imatinib. (LASOR)
  • A randomised, controlled, double-blind phase iii trial to compare the efficacy, safety and pharmacokinetics of XXX plus CVP vs. MabThera® plus CVP, followed by XXX or MabThera® 
  • A randomised, controlled, double-blind phase iii trial to compare the efficacy, safety and pharmacokinetics of XXX plus CVP vs. MabThera® plus CVP, followed by XXX or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphomaprospective, multi-centric, open label, two arm, parallel group, active control, randomised, comparative clinical study to evaluate efficacy and safety of XXX/MabThera® in patients with follicular B-Cell Non-Hodgkin's lymp
  • Medullary cervical neurinoma presenting as progressive spastic hemiparesis. Neurology India. Sep 1990; Vol. 38, No. 5, Page 494
  • Diurnally fluctuating hereditary progressive dystonia with typical feature. Neurology India. 1994; 41, 7-39
  • An unusual association of adult polycystic kidney disease. Neurology India. 1994; 42
  • Primary reading epilepsy. A case report. Neurology India. 1996; 44, 25-26
  • Cerebral venous and arterial thrombosis in pregnancy and puerperium – A prospective, study. JAPI. 1997; Vol. 45, No. 11, 857-859
  • Asymptomatic Radiological cerebella atrophy with chronic antiepileptic therapy. JANE I. 1997; 2 (I), 69-70
  • TIA caused by small basal ganglia hematoma. JAPI (Accepted for publication)
  • Benign intracranial hypertension – A review. Rajasthan Medical Journal (Accepted for publication)
  • Recent trends in neurocysticercosis in India. Rajasthan Medical Journal (Accepted for publication)
  • Diagnosis of malaria by detection of plasmodium falciparum HRP-2 antigen with rapid dipstick Antigen capture assay. Rajasthan Medical Journal (Accepted for publication)
  • Wilson’s disease – A review. Rajasthan Medical Journal (Accepted for publication)
  • Stroke in young in north-western Indian. 1st International Conference on ODNS. Nov 1994
  • Chemotherapy in non small cell lung cancer. 53rd Annual Conference of API. Jan 1998
  • Interferon Alfa in chronic myeloid leukaemia. Biennial Conference of ISMPO. Jan 1999
  • Poster Presentation: Breast cancer-Review of presentation and management. 17th APCC, Bali. Oct 2003
  • Member, Indian Society of Medical and Paediatric Oncology
  • Member, Indian Society of Haematology and Transfusion Medicine
  • Member, Indian Co-operative Oncology Network
  • Member, Indian CML Study Group
  • Member, Brain Tumour Study Group
  • Key Opinion Leader for Biocon India Ltd
  • Key Opinion Leader for Celltrion, South Korea